Predictors of severe COVID-19: older age and comorbidity

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap.

AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients.

METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated.

RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups.

CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.

About the authors

Vladislav V. Konnov

Infectious Clinical Hospital No 2, Moscow; Sechenov First Moscow State Medical University

Email: konnov.vlad@gmail.com
ORCID iD: 0000-0002-4978-4139
SPIN-code: 6228-2241

MD

Russian Federation, Moscow; Moscow

Anna E. Tsygankova

Infectious Clinical Hospital No 2, Moscow; Sechenov First Moscow State Medical University

Author for correspondence.
Email: anna.tsygankova.inf@gmail.com
ORCID iD: 0000-0003-3766-1868
SPIN-code: 6583-0476

MD, Cand. Sci. (Medicine);

Russian Federation, Moscow; Moscow

Andrey N. Gerasimov

Centre for Strategic Planning and Management of Biomedical Health Risks

Email: andr-gerasim@yandex.ru
ORCID iD: 0000-0003-4549-7172
SPIN-code: 4742-1459

Dr. Sci. (Physics and Mathematics), Assistant Professor

Russian Federation, Moscow

Ksenia A. Timonina

Sechenov First Moscow State Medical University

Email: ksuchatimonina@gmail.com
ORCID iD: 0009-0005-9764-8106
Russian Federation, Moscow

Natalia A. Tsvetkova

Infectious Clinical Hospital No 2, Moscow

Email: 3655192@mail.ru
ORCID iD: 0000-0003-3323-3401
SPIN-code: 5322-6167

MD, Cand. Sci. (Medicine);

Russian Federation, Moscow

Svetlana A. Potekaeva

Infectious Clinical Hospital No 2, Moscow

Email: infection_mma@mail.ru
ORCID iD: 0000-0002-4771-9616
SPIN-code: 6105-8492

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Karina T. Umbetova

Sechenov First Moscow State Medical University

Email: karinasara@inbox.ru
ORCID iD: 0000-0003-0902-9267
SPIN-code: 3197-9205

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Elena V. Volchkova

Sechenov First Moscow State Medical University

Email: antononina@rambler.ru
ORCID iD: 0000-0003-4581-4510
SPIN-code: 3342-4681

MD, Dr. Sci (Medicine), Professor

Russian Federation, Moscow

References

  1. Samadizadeh S, Masoudi M, Rastegar M, et al. COVID-19: Why does disease severity vary among individuals? Respir Med. 2021;180:106356. doi: 10.1016/j.rmed.2021.106356 EDN: MGJJJQ
  2. Morani I, Shibli H, Karasik D, Edelstein M. Determining population-specific risk factors for COVID-19 susceptibility and severity to inform future individual-level integrated risk scoring. BMC Infect Dis. 2025;25(1):977. doi: 10.1186/s12879-025-11357-9
  3. Satué-Gracia EM, Vila-Córcoles A, de Diego-Cabanes C, et al. Susceptibility and risk of SARS-CoV-2 infection among middle-aged and older adults in Tarragona area, Spain. Med Clin (Barc). 2022;158(6):251–259. doi: 10.1016/j.medcli.2021.03.027 EDN: PRPXFS
  4. Radygina LV, Mochalova LV. Factors affecting the severity of COVID-19 and the development of complications. Microbiology Independent Research Journal (MIR Journal). 2023;10(1):20–38. doi: 10.18527/2500-2236-2023-10-1-20-38.RU EDN: AHCRUR
  5. Tsygankova AE, Gerasimov AN, Chulanov VP, et al. Previously diagnosed HIV infection in patients with COVID-19 and advanced HIV disease improves their survival. Arch Clin Infect Dis. 2023;18(5):e142231. doi: 10.5812/archcid-142231 EDN: PQVNXN
  6. Tkacheva ON, Kotovskaya YuV, Aleksanyan LA, et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601. doi: 10.15829/1728-8800-2020-2601 EDN: LONZLO
  7. Farshbafnadi M, Kamali Zonouzi S, Sabahi M, et al. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp Gerontol. 2021;154:111507. doi: 10.1016/j.exger.2021.111507 EDN: VGHNTU
  8. Avdeev SN, Gaynitdinova VV, Pozdniakova AA, et al. Risk factors for adverse outcomes in elderly patients with asthma and severe COVID-19 at the hospital and early post-hospital stages. Terapevticheskii Arkhiv. 2023;95(1):57–65. doi: 10.26442/00403660.2023.01.202049 EDN: GPLACG
  9. Schultz MJ, van Oosten PJ, Hol L. Mortality among elderly patients with COVID-19 ARDS — age still does matter. Pulmonol. 2023;29(5):353–355. doi: 10.1016/j.pulmoe.2023.02.013 EDN: ZHVXVI
  10. Sharipova MM, Ivkina MV, Arkhangelskaia AN, et al. Features of the course of COVID-19 in patients with comorbid pathology. Meditsinskiy sovet = Medical Council. 2022;(6):44–49. doi: 10.21518/2079-701X-2022-16-6-44-49 EDN: RSITDA
  11. Warren-Gash C, Davidson JA, Strongman H, et al. Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur. 2023;27:100604. doi: 10.1016/j.lanepe.2023.100604 EDN: AOHLZQ
  12. Hall EJ, Ayers CR, Kolkailah AA, et al. Longitudinal trends in cardiovascular risk factor profiles and complications among patients hospitalized for COVID-19 infection: results from the american heart association COVID-19 cardiovascular disease registry. Circ Cardiovasc Qual Outcomes. 2023;16(5):e009652. doi: 10.1161/CIRCOUTCOMES.122.009652 EDN: ZLOJWZ
  13. Mokrysheva NG, Shestakova MV, Vikulova OK, et al. Analysis of risk factors for COVID-19-related fatal outcome in 337991 patients with type 1 and type 2 diabetes mellitus in 2020–2022 years: Russian nationwide retrospective study. Diabetes Mellitus. 2022;25(5):404–417. doi: 10.14341/DM12954 EDN: TYFVHG
  14. Al-Azzam N, Al-Azzam S, Khassawneh B, et al. Factors contributing to poor COVID-19 outcomes in diabetic patients: Findings from a single-center cohort study. PLoS One. 2023;18(8):e0290946. doi: 10.1371/journal.pone.0290946 EDN: YLPCYJ
  15. Mara G, Nini G, Cotoraci C. Chronic obstructive pulmonary disease and COVID-19: The impact of hematological biomarkers on disease severity and outcomes. J Clin Med. 2025;14(8):2765. doi: 10.3390/jcm14082765
  16. Avdeev SN, Adamyan LV, Alexeeva EI, et al. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Versions 1–17 [Internet] [cited 2025 Nov 25]. (In Russ.) Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/%D0%92%D0%9C%D0%A0_COVID-19_V18.pdf EDN: PDXQNY
  17. Age-friendly environments in Europe: Indicators, monitoring and assessments. Copenhagen: World Health Organization Regional Office for Europe; 2018 [cited 2025 Aug 7]. ISBN: 978-9-2890-5777-6 Available from: https://www.who.int/europe/ru/publications/i/item/WHO-EURO-2018-1088-40834-55192
  18. Wang A, Li K, Sun H, et al. Assessing the impact of comorbidities on disease severity in COVID-19 patients requires consideration of age. Medicine. 2025;104(5):e41360. doi: 10.1097/md.0000000000041360 EDN: NOUPZP
  19. Ge E, Li Y, Wu S, et al. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One. 2021;16(10):e0258154. doi: 10.1371/journal.pone.0258154 EDN: DLVCYI
  20. Patrascu R, Dumitru CS, Laza R, et al. The role of age and comorbidity interactions in COVID-19 mortality: insights from cardiac and pulmonary conditions. J Clin Med. 2024;13(24):7510. doi: 10.3390/jcm13247510 EDN: FSZPEN
  21. Cai R, Zhang J, Zhu Y, et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol. 2021;53(8):1623–1629. doi: 10.1007/s11255-020-02740-3 EDN: FTUWOP
  22. Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021;11(1):21. doi: 10.1038/s41387-021-00163-2 EDN: MCMYUO
  23. Jani CT, Schooley RT, Mckay RR, Lippman SM. Cancer, more than a “COVID-19 co-morbidity”. Front Oncol. 2023;13:1107384. doi: 10.3389/fonc.2023.1107384
  24. Abul Y, Leeder C, Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect Dis Clin North Am. 2023;37(1):1–26. doi: 10.1016/j.idc.2022.11.001 EDN: KBYPMZ
  25. Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11(5):453–464. doi: 10.1016/S2213-2600(22)00528-8 EDN: GSIBDQ

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2026 Eco-vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).